Novo Nordisk’s blockbuster type 2 diabetes medication is a sure bet for the list of the next 15 drugs whose Medicare prices ...

About a month after reporting it’s had a tough time starting enough patients on its treatments, bluebird bio announced it ...

Before companies and investors look towards the future, they must first understand the opportunities and challenges AI ...

Clinical trial results shared by Boehringer Ingelheim and Insilico Medicine showed improvement in idiopathic pulmonary ...

Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure they stay there as competition enters, the companies are spending billions in ...

Amid a flurry of weight loss readouts, a fresh-on-the-scene startup has come out with Phase I results showing weight loss at day 36 on par with or better than competitors, with few gastrointestinal ...

A senior senator has asked the CEOs of both companies to provide information about the limits they are putting on 340B drug ...